Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysacchari...

Descrizione completa

Dettagli Bibliografici
Autori principali: Hannah M. Garcia Garrido, Albert Vollaard, Geert R. D’Haens, Phyllis I. Spuls, Frederike J. Bemelman, Michael W. Tanck, Godelieve J. de Bree, Bob Meek, Martin P. Grobusch, Abraham Goorhuis
Natura: Articolo
Lingua:English
Pubblicazione: MDPI AG 2022-05-01
Serie:Vaccines
Soggetti:
pneumococcal vaccination
immunocompromised host
transplant recipient
autoimmune disease
vaccine immunogenicity
Accesso online:https://www.mdpi.com/2076-393X/10/5/795

Accesso online

https://www.mdpi.com/2076-393X/10/5/795

Documenti analoghi